samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

WCCT Global (an Altasciences Company) Clinic Expansion

Altasciences



Laval, Quebec, March 23, 2021 –
WCCT Global, an Altasciences company, announced the expansion of their clinical pharmacology unit and laboratory earlier this year. Today, Altasciences confirms the unit dosed its first study participants. The expansion added 5,000 square feet of configurable clinical trial facilities. This further ensures participants have access to a socially distanced, comfortable space in which to complete study procedures. An additional 700 square feet of lab space was also added. Read the original press release.

“We are thrilled to be able to provide more functional space for our study participants and staff, and create a dosing environment that can support blinded administrations of medications. This expansion increases unit capacity, operational efficiency, and freedom of movement. We look forward to showcasing our brand-new expansion to our clients and for our subjects to have added comfort during their participation at our site,” said Dr. David Nguyen, Chief Medical and Operations Officer at WCCT Global, an Altasciences company.

Chris Perkin, CEO of Altasciences, adds, “The dosing of the first participants in our West Coast clinic expansion is an important milestone in the evolution of our clinical trial offerings, for both long-term stays and outpatient visits. We are excited to see it come to fruition and for its contribution to Altasciences’ continued growth to support early-stage drug development.” Altasciences acquired WCCT Global on February 12, 2021, adding a third clinical location to existing facilities in Kansas City, U.S.A. and Montreal, Canada. Read the acquisition press release.

About Altasciences

Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
phone 450 973-6077
email contact@altasciences.com
web www.altasciences.com
email 575 Armand-Frappier Blvd. Laval, QC H7V 4B3 Canada
 
Print this page
Send to a friend
   
spacer
News and Press Releases

CARMAT Announces the First Human Implant of its Total Artificial Heart in the United States

Paris, July 15, 2021 - 7 am CEST CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the first implantation of its bioprosthetic artificial heart, Aeson®, in the United States within the framework of the Early Feasibility Study (EFS).
More info >>


White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement